Showing posts with label chronic obstructive pulmonary disease. Show all posts
Showing posts with label chronic obstructive pulmonary disease. Show all posts

Friday, 20 August 2010

COPD management is effectively managed with steroids

The use of inhaled steroids can be extremely useful for reducing the mortality rate associated with in COPD (chronic obstructive pulmonary disease), according to a study appearing in an issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP).
It was reported by the study that patients making use of steroids in pairing with beta-agonists tend to notice a reduction in cardiovascular-related death alone by 38 percent.
Dr. Macie and colleagues found that the mortality rates in patients 65+ who received inhaled corticosteroids were 11.7 percent, compared with 13.1 percent for those who did not. Patients in the younger group showed even greater results, with a mortality rate of 3.0 percent for patients receiving inhaled corticosteroids within 90 days, compared with 6.0 percent for those who did not, providing a mortality reduction rate of 53 percent. When patients who received steroids in the year prior were removed from the analysis, mortality was reduced by 34 percent. Researchers attribute this finding to multifactorial reasons, including reductions in exacerbations of the disease and suppression of inflammation.
Researchers also found a 23 percent reduced risk of death when comparing the effects of inhaled steroids with bronchodilators in patients in the 65+ group. In all cases, the most significant results were found when inhaled corticosteroids were administered within the first 30 days following hospital discharge.
W. Michael Alberts, MD, FCCP, President of the ACCP, remarked that findings of this study have implications for clinicians and suggest the requirement of further research in order to define the roles and mechanisms of the effects of inhaled steroids on both respiratory and cardiovascular mortality.

Friday, 12 March 2010

Entest BioMedical files third patent application

A third patent application was recently filed by Entest BioMedical Inc. (OTC Bulletin Board: ENTB) in concern to COPD (chronic obstructive pulmonary disease).
COPD is believed to affect more than 5 million people in the United States alone and claims around 120,000 deaths every year.
It is important to note here that a recent article "Immunologic aspects of chronic obstructive pulmonary disease" by Cosio et al in the June 4th, 2009 issue of New England Medical Journal had suggested that COPD is not just a disease of inflammation but more of an active immunological attack.
"To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy. The current patent application has a variety of derivative uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry," stated David Koos, Entest's CEO.
The essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes. Instead of us "telling the body" what it should do with a blunt-force approach, as is the standard of care, the current invention uses more natural and slow acting interventions.
Dr. Stephen Josephs, inventor of the technology, said that significance of the inflammatory process in COPD is exemplified by use of broad-acting steroids used to reduce inflammation but they can bring adverse effects.

Thursday, 24 September 2009

John Hopkins experts call for greater caution for prescribing inhaled corticosteroids

Lung disease experts at Johns Hopkins have made a call for greater caution for prescribing inhaled corticosteroids to people suffering from chronic obstructive pulmonary disease (COPD). The call came after sufficient evidence was found by the experts that inhaled corticosteroids enhance the risk of pneumonia by a full third.
It is believed that more than 11 million Americans are living with COPD and a vast majority of this population belongs to the former or current smokers' category.
From News-Medical.Net:
Despite the increased pneumonia risk, the team found no clear evidence that the drug therapy also pushes up rates for other steroid-related problems, such as bone fractures, nor was there an increase in deaths.
Senior study investigator and critical care specialist Eddy Fan, M.D., says the results of the analysis should not alarm patients or cause them to stop taking their medications but should spur physicians to screen and monitor their patients to find the lowest possible steroid dose that works, especially in the elderly, people with immune system problems, and people who have had multiple bouts of pneumonia and for whom repeat bacterial infection might be a life-threatening complication.
"Inhaled corticosteroids are not of equal benefit to all, and what we are seeing is that the treatment may be more harmful and pose a greater risk of harm to some," says Fan, an instructor at the Johns Hopkins University School of Medicine.
According to pulmonologist M. Brad Drummond, M.D., M.H.S., who led the study, the findings are seen to serve as a reminder for all those people with serious lung disease to take steps for ensuring a reduction concerned with chances of getting pneumonia, which doubles their risk of dying.

Wednesday, 16 September 2009

Prolonged usage of a macrolide antibiotic reduces COPD exacerbations


Prolonged usage of a macrolide antibiotic could possible minimize exacerbations in patients with moderate to severe COPD (chronic obstructive pulmonary disease) by as much as 35 percent as per a London-based study.
According to lead author of the paper, Terence A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D., principle investigator, there is a considerable effect of low-dose macrolide therapy, reducing exacerbation frequency, and severity with moderate to severe COPD.
From News-Medical.Net:
The researchers found that not only did the patients randomized to receive erythromycin have fewer exacerbations, but among the patients studied, 60 percent of the exacerbations that occurred were within the placebo group. While the number of exacerbation-related hospitalizations was small, more than twice as many occurred among the placebo group—14 versus 6. The median duration of exacerbations from onset to resolution of symptoms was 9 days in the erythromycin group and 13 days in the placebo group.
"Our results did not allow us to determine a mechanism for these findings. However based on in-vitro studies we suspect that the mechanism is likely to involve the anti-inflammatory properties of erythromycin," noted Dr. Seemungal.
While their findings are encouraging, Dr. Seemungal points out that they must be put in context with future findings. Furthermore, the threat of growing antibiotic resistance resulting from widespread prophylactic use of erythromycin is not a trivial concern. "In this scenario, substantial, widespread emergence of macrolide bacterial resistance is virtually foreordained, with attendant reduction in the antimicrobial usefulness of this drug class," wrote Ken M. Kunisaki, M.D. and Denise E. Niewoehner, M.D., of the Veterans Affairs Medical Center in Minneapolis, in the accompanying editorial. "Balancing benefit against harm could pose a dilemma for which there might be no clear answers."
John Heffner, M.D., past president of the ATS, was of the view that observations that intervention might possibly minimize the frequency and severity of acute exacerbations in COPD showcase present significant public health implications.

Tuesday, 16 June 2009

COPD Patients to benefit from Inhaled Corticosteroids

As per a new study published in the CHEST, a peer-reviewed journal of the American College of Chest Physicians, COPD (Chronic obstructive pulmonary disease) patients using inhaled corticosteroids are believed to have a decreased mortality risk than who do not use them.

The survival is longer in patients with COPD who make use of inhaled corticosteroids, as per Christine Macie, MD, FCCP, Cambridge Hospital, Ontario, Canada and author of this study.

From Bio-medicine.org:

“Our results indicate that the effect of inhaled corticosteroids is relatively short-term and that those currently using it are relatively better protected, ” said Dr. Macie. “Inhaled corticosteroids should be prescribed as soon as clinically indicated. By treating COPD with inhaled corticosteroids, we have the potential to reduce the effect and prolong life.”

“The findings from this study are intriguing for clinicians and point to the need for further research to define the role and mechanisms of the effect of inhaled corticosteroids on both cardiovascular and respiratory mortality,” said W. Michael Alberts, MD, FCCP, President of the ACCP.

During the study, it was found that COPD patients being administered with inhaled corticosteroids within 30 days of their hospital discharge had a 25 percent reduced all-cause mortality rate. In addition to that, cardiovascular related mortality reduced by as much as 38 percent in COPD patients using corticosteroids in pair with beta-agonists.

Dr. Macie also said that COPD Patients making use of inhaled corticosteroids are relatively better protected than those who are not making a use of it.